Ixekizumab (Taltz®)
Taltz® is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.
Rapid Review
| Commenced | Completed | Outcome |
| 28/06/2016 | 26/07/2016 | Full Pharmacoeconomic Evaluation Recommended at the Submitted Price |
September 2016
The HSE has approved reimbursement following confidential price negotiations.